<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373580</url>
  </required_header>
  <id_info>
    <org_study_id>P09-0003</org_study_id>
    <nct_id>NCT01373580</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near Vision in Presbyopic Patients</brief_title>
  <official_title>A Prospective, Multinational Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc. PresbyLens Corneal Inlay for the Improvement of Near Vision in Presbyopic Subjects With MRSE From -0.50 to +1.00</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReVision Optics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReVision Optics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a prospective, multicenter clinical trial in which a total of 400 subjects
      will be enrolled. All subjects will be followed over a 36 month time frame with a maximum of
      15 clinical sites participating. Qualified subjects will provide informed consent for entry
      into the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The loss of near vision and the ability to perform tasks that require near vision is part of
      the normal aging process. This natural transformation in the eye occurs as a result of the
      loss of accommodation of the crystalline lens, a condition known as presbyopia. Presbyopia,
      characterized by a progressive, age-related loss of accommodation (i.e., the lens ability to
      focus clearly over a wide range of distances), is most prevalent of all visual deficiencies,
      affecting 100% of the population over the course of a normal life span. Loss of accommodation
      begins early in life and, for an emmetropic eye, generally culminates in a complete loss of
      functional near vision.

      ReVision Optics has developed the Raindrop corneal inlay for the correction of near vision.
      The Raindrop is a 2mm corneal inlay, as small as a pinhead, thinner than a human hair and
      about 1/500th of a droplet of water. The inlay is the same refractive index as the human
      cornea. The inlay is placed in the non-dominant eye,centered over the pupil after a corneal
      flap (LASIK)has been made. The Raindrop is expected to provide presbyopic subjects with
      improvement of near and intermediate vision.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Improvement in Uncorrected Near Visual Acuity (20/40 or Better) in the Implanted Eye</measure>
    <time_frame>24 Months</time_frame>
    <description>75% of participants should achieve uncorrected near visual acuity in the implanted eye of 20/40 or better as compared to preoperative baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With no or Minimal Loss of Best Corrected Visual Acuity in the Implanted Eye</measure>
    <time_frame>at 6 months postoperative and all subsequent visits</time_frame>
    <description>Less than 5% of participants should lose more than two lines of best corrected distance and near visual acuity in the implanted eye; and less than 1% of participants with preoperative best spectacle corrected visual acuity (BCDVA) of 20/20 in the implanted eye should have best corrected distance and near visual acuity worse than 20/40 in the implanted eye at 6 months postoperative and all subsequent visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Induced Manifest Refractive Astigmatism in the Implanted Eye</measure>
    <time_frame>At 6 months postoperative and all subsequent visits</time_frame>
    <description>Less than 5% of participants should have postoperative manifest refractive astigmatism in the implanted eye that increases from baseline by greater than 2.00 D at 6 months postoperative and all subsequent visits.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">373</enrollment>
  <condition>Presbyopia</condition>
  <arm_group>
    <arm_group_label>Raindrop</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Raindrop Near Vision Inlay</intervention_name>
    <description>The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia</description>
    <arm_group_label>Raindrop</arm_group_label>
    <other_name>Presbylens</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        must be presbyopic adults, needing from +1.50 to +2.50 or reading add must have uncorrected
        near visual acuity worse than 20/40 and better than 20/200in the eye to be implanted must
        have an uncorrected distance visual acuity of 20/25 or better in both eyes must have a
        distance visual acuity correctable to 20/20 in both eyes must have a near visual acuity
        correctable to 20/20 in both eyes must have a manifest refraction spherical equivalent
        between -0.50 and +1.00D in the eye to be implanted with no more than 0.75D of refractive
        cylinder must report stable vision, i.e. no change in distance vision and or MRSE within
        0.50D over prior 12 months must discontinue hard or rigid gas permeable lenses for at least
        3 weeks and discontinue soft lenses for at least 1 week prior to baseline examination must
        have a minimum central corneal thickness of &gt;500 microns in the eye to be implanted must
        have a mesopic pupil &lt; 7.0mm and photopic pupil &gt;3.0mm in the eye to be implanted subjects
        aged 45 years or younger must have an endothelial cell count

        Exclusion Criteria:

        Subjects with a difference of &gt;0.75 between the manifest refraction spherical equivalent
        and the cycloplegic refraction spherical equivalent Subjects with anterior segment
        pathology, including clinically significant cataracts, in the non-dominant eye Subjects
        with residual, recurrent, active ocular or uncontrolled eyelid disease, or any corneal
        abnormality (including endothelial dystrophy, guttata, recurrent corneal erosion, etc.) in
        the non-dominant eye Subjects with ophthalmoscopic signs of keratoconus (or keratoconus
        suspect) in the non-dominant eye Subjects with clinically significant dry eyes, as
        determined by either the presence of greater than mild symptoms of dryness or discomfort or
        SPK greater than grade 1 Subjects with distorted or unclear mires on topography maps of the
        non-dominant eye Subjects with macular degeneration, retinal detachment, or any other
        fundus pathology that would prevent an acceptable visual outcome in the non-dominant eye
        Subjects who have undergone LASIK surgery in the non-dominant eye Subjects with a history
        of herpes zoster or herpes simplex keratitis Subjects who have a history of steroid
        responsive rise in intraocular pressure, pre-operative IOP&gt;21 mm Hg, glaucoma or are a
        glaucoma suspect Subjects with a history of diagnosed diabetes, autoimmune disease,
        connective tissue disease, or clinically significant atopic syndrome Subjects on chronic
        systemic corticosteroids or other immunosuppressive therapy that may affect wound healing,
        and any immunocompromised subjects Subjects who are using ophthalmic mediation(s) other
        than artificial tears for treatment of any ocular pathology Subjects using systemic
        medications with significant ocular side effects Subjects who are pregnant, lactating, or
        planning to become pregnant during the course of the study Subjects what are participating
        in any other ophthalmic drug or device studies during the time of this clinical
        investigation Subjects with known sensitivity to planned study concomitant medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven G Slade, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jon G Dishler, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>John Olkowski, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Dan B Tran, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Ralph Y Chu, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey Whitman, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Robert P Lehmann, M.D.</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Gregory Parkhurst, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unaffilliated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harvey L Carter, III, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unaffilliated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Dougherty, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unaffilliated</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Hovanesian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unaffilliated</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dougherty Laser Vision</name>
      <address>
        <city>Camarillo</city>
        <state>California</state>
        <zip>93010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vision</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jon G. Dishler, M.D.</name>
      <address>
        <city>Greenwood Village</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eyesight Hawaai</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Vision</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Key-Whitman Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carter Eye Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slade and Baker Vision Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehmann Eye Center</name>
      <address>
        <city>Nacogdoches</city>
        <state>Texas</state>
        <zip>75965</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NuVision.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2011</study_first_posted>
  <results_first_submitted>October 11, 2017</results_first_submitted>
  <results_first_submitted_qc>March 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2018</results_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>presbyopia</keyword>
  <keyword>LASIK</keyword>
  <keyword>loss of accommodation</keyword>
  <keyword>Emmetrope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Presbyopia</mesh_term>
    <mesh_term>Myopia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raindrop</title>
          <description>A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
The Raindrop Near Vision Inlay: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="373"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="317"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raindrop</title>
          <description>A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
The Raindrop Near Vision Inlay: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="373"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.3" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Improvement in Uncorrected Near Visual Acuity (20/40 or Better) in the Implanted Eye</title>
        <description>75% of participants should achieve uncorrected near visual acuity in the implanted eye of 20/40 or better as compared to preoperative baseline</description>
        <time_frame>24 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Raindrop</title>
            <description>A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
The Raindrop Near Vision Inlay: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Uncorrected Near Visual Acuity (20/40 or Better) in the Implanted Eye</title>
          <description>75% of participants should achieve uncorrected near visual acuity in the implanted eye of 20/40 or better as compared to preoperative baseline</description>
          <units>Count of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With no or Minimal Loss of Best Corrected Visual Acuity in the Implanted Eye</title>
        <description>Less than 5% of participants should lose more than two lines of best corrected distance and near visual acuity in the implanted eye; and less than 1% of participants with preoperative best spectacle corrected visual acuity (BCDVA) of 20/20 in the implanted eye should have best corrected distance and near visual acuity worse than 20/40 in the implanted eye at 6 months postoperative and all subsequent visits.</description>
        <time_frame>at 6 months postoperative and all subsequent visits</time_frame>
        <population>Numbers analyzed at each timepoint differ due to participant availability</population>
        <group_list>
          <group group_id="O1">
            <title>Raindrop</title>
            <description>A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
The Raindrop Near Vision Inlay: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With no or Minimal Loss of Best Corrected Visual Acuity in the Implanted Eye</title>
          <description>Less than 5% of participants should lose more than two lines of best corrected distance and near visual acuity in the implanted eye; and less than 1% of participants with preoperative best spectacle corrected visual acuity (BCDVA) of 20/20 in the implanted eye should have best corrected distance and near visual acuity worse than 20/40 in the implanted eye at 6 months postoperative and all subsequent visits.</description>
          <population>Numbers analyzed at each timepoint differ due to participant availability</population>
          <units>Count of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title># of participants@6M w/loss &gt;/= 2 lines of BCVA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@9M w/loss &gt;/= 2 lines of BCVA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@12M w/loss &gt;/= 2 lines of BCVA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@18M w/loss&gt;/= 2 lines of BCVA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participant@24M w/loss &gt;/= 2 lines of BCVA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@6M w/BCDVA or BCNVA &lt; 20/40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@9M w/BCDVA or BCNVA &lt; 20/40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@12M w/BCDVA or BCNVA &lt; 20/40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@18M w/BCDVA or BCNVA &lt; 20/40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title># of participants@24M w/BCDVA or BCNVA &lt; 20/40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Induced Manifest Refractive Astigmatism in the Implanted Eye</title>
        <description>Less than 5% of participants should have postoperative manifest refractive astigmatism in the implanted eye that increases from baseline by greater than 2.00 D at 6 months postoperative and all subsequent visits.</description>
        <time_frame>At 6 months postoperative and all subsequent visits</time_frame>
        <population>Numbers analyzed at each timepoint differ due to participant availability.</population>
        <group_list>
          <group group_id="O1">
            <title>Raindrop</title>
            <description>A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
The Raindrop Near Vision Inlay: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Induced Manifest Refractive Astigmatism in the Implanted Eye</title>
          <description>Less than 5% of participants should have postoperative manifest refractive astigmatism in the implanted eye that increases from baseline by greater than 2.00 D at 6 months postoperative and all subsequent visits.</description>
          <population>Numbers analyzed at each timepoint differ due to participant availability.</population>
          <units>Count of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>#of participants@6M w/&gt;2D increase in astigmatism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="365"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>#of participants@9M w/&gt;2D increase in astigmatism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="364"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>#of participants@12M w/&gt;2D increase in astigmatism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>#of participants@18M w/&gt;2D increase in astigmatism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>#of participants@24M w/&gt;2D increase in astigmatism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1, Week 1, Months 1, 2, 3, 6, 9, 12, 18, 24, 30, 36</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Raindrop</title>
          <description>A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near vision.
The Raindrop Near Vision Inlay: The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for elevated blood sugar</sub_title>
                <description>Non-ocular and not related to device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization secondary to heart disease</sub_title>
                <description>Non-ocular and not related to device</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Melting of the flap</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Surgery to repair orbital bone fracture</sub_title>
                <description>Relationship to device unknown</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to Ischemic Colitis</sub_title>
                <description>Non-ocular and not related to device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Not related to device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Hospitalization due to adverse reaction to medication</sub_title>
                <description>Infection to medication given to treat infection following surgery Seizure, reaction to systemic medication
Non-ocular and not related to device</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Hospitalization for fainting/upper extremity pain - no formal diagnosis</sub_title>
                <description>Non-ocular and not related to device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Infection secondary to achilles tendon surgery</sub_title>
                <description>Non-ocular and not related to device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Transient Ischemic Attack</sub_title>
                <description>Non-ocular and not related to device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to Pneumonia</sub_title>
                <description>Non-ocular and not related to device</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalization secondary to other surgery</sub_title>
                <description>Transforminal lumbar fusion Cervical fusions with implanted plate and rods Pancreatectomy, Splenectomy (cancer) Gall Bladder removal Nephrectomy Emergency Appendectomy (2) Radical prostatectomy
Non-ocular and not related to device</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Epithelial ingrowth</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Loss in BCDVA of &gt; 2 lines (11 letters or more) at 3 months or later</sub_title>
                <description>BCDVA = Best Corrected Distance Visual Acuity</description>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Late onset of haze beyond 6 months with loss of 2 lines (10 letters) or more BCVA</sub_title>
                <description>BCVA = Best Corrected Visual Acuity</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Cataract (with loss in BCDVA greater than or equal to 2 lines at any time</sub_title>
                <description>BCDVA = Best Corrected Distance Visual Acuity</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Increase in Intraocular Pressure of greater than 10mmHg above baseline</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Diffuse Lamellar Keratitis (DLK)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Secondary Surgical Intervention</sub_title>
                <description>Inlay Exchange = 18 Inlay Explant = 38 Flap Lift = 4 Cataract Surgery = 1</description>
                <counts group_id="E1" events="62" subjects_affected="54" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Posterior Vitreous Detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Transient Visual Disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Anterior Uveitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Corneal Epithelial Defect Involving the Keratectomy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Broken Orbital Bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
              <event>
                <sub_title>Lost, Misaligned, or Misplaced Flap</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="373"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agreed to hold this information in confidence and not to disclose it to any third parties for a period of three years from the date of this agreement, or until this information becomes a matter of public knowledge or until a formal agreement for that purpose has been entered into by the parties.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tracy Shwaery, Global Clinical Research Manager</name_or_title>
      <organization>ReVision Optics</organization>
      <phone>9497072740 ext 157</phone>
      <email>tshwaery@revisionoptics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

